Trials / Unknown
UnknownNCT03460925
Improving REsectability in Pancreatic NEoplasms (IRENE)
Interventional Multicentric Study Without Medicine, in Patients Affected by Locally Advanced Pancreatic Adenocarcinoma: Stereotactic Radiotherapy.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of clinical response in terms of resectability of patients with locally advanced pancreatic cancer treated with neoadjuvant chemotherapy plus stereotactic body radiotherapy.
Detailed description
Aim of the study is to define the percentage of patients with down-staging and clinical response after having undergone stereotactic radiotherapy + chemotherapy with neoadjuvant intent for locally advanced pancreatic carcinoma or "borderline resectable" at the time of diagnosis. The study evaluates the response to therapy in terms of resectability, of acute and delayed treatment-related toxicity, of overall survival and progression-free survival and also assesses patient's quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SBRT plus chemotherapy | Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox |
Timeline
- Start date
- 2018-05-02
- Primary completion
- 2020-01-01
- Completion
- 2021-01-01
- First posted
- 2018-03-09
- Last updated
- 2018-05-30
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03460925. Inclusion in this directory is not an endorsement.